Skip to main navigation Skip to search Skip to main content

Corrigendum to “Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus” [Heliyon 9(4) (April 2023) e15032] (Heliyon (2023) 9(4), (S2405844023022399), (10.1016/j.heliyon.2023.e15032))

  • Nancy E. Hernandez
  • , Wojciech Jankowski
  • , Rahel Frick
  • , Simon P. Kelow
  • , Joseph H. Lubin
  • , Vijaya Simhadri
  • , Jared Adolf-Bryfogle
  • , Sagar D. Khare
  • , Roland L. Dunbrack
  • , Jeffrey J. Gray
  • , Zuben E. Sauna
  • United States Food and Drug Administration
  • Johns Hopkins University
  • Fox Chase Cancer Center
  • University of Pennsylvania
  • Rutgers - The State University of New Jersey, New Brunswick
  • Institute for Protein Innovation

Research output: Contribution to journal › Comment/debate

2 Scopus citations

Abstract

In the original published version of this article, some supplementary data was missing. This has now been provided by the author. The authors apologize for the errors. Both the HTML and PDF versions of the article have been updated to correct the errors.

Original languageEnglish
Article numbere17901
Pages (from-to)e17901
JournalHeliyon
Volume9
Issue number8
DOIs
StatePublished - Aug 2023

Fingerprint

Dive into the research topics of 'Corrigendum to “Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus” [Heliyon 9(4) (April 2023) e15032] (Heliyon (2023) 9(4), (S2405844023022399), (10.1016/j.heliyon.2023.e15032))'. Together they form a unique fingerprint.

Cite this